News Conference News AHA 2025 POLY-HF: Polypill Pays Dividends in Patients With HFrEF Todd Neale November 14, 2025
News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Conference News AHA 2022 Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions Yael L. Maxwell November 01, 2022
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Conference News AHA 2020 One in Five Patients Admitted With COVID-19 Die in the Hospital Michael O'Riordan November 20, 2020
News Conference News AHA 2020 Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF Todd Neale November 13, 2020
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News AHA 2018 PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure Michael O'Riordan November 11, 2018
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2017 Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I Michael O'Riordan November 21, 2017
News Conference News AHA 2013 RADAR-AF: HF Source Ablation Does Not Benefit Paroxysmal, Persistent A-fib Patients Yael L. Maxwell November 19, 2013